Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HMGB3P27 (high mobility group box 3 pseudogene 27) is classified as a pseudogene of the high mobility group (HMG) family. Pseudogenes like HMGB3P27 result from duplication or mutation of functional genes—in this case, HMGB3—which encode DNA-binding proteins involved in chromatin structure and transcriptional regulation. Pseudogenes typically do not produce functional proteins; their transcripts may be non-functional or rarely contribute to regulatory functions, potentially affecting the expression of homologous protein-coding genes through RNA interference or other mechanisms, although no function has been specifically established for HMGB3P27. It is not considered a canonical therapeutic target or biomarker, and no drugs are known to interact with it[4][1][11][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box 3 pseudogene 27 (HMGB3P27).